Table 6 Laboratory data of patients classified by serological status of HEV during 2015–2018
Laboratory data | Age (years) | AST (U/L) | ALT (U/L) | ALP (U/L) | Total bilirubin (mg/dL) |
|---|---|---|---|---|---|
All cases (n = 796) | 49 (0.03–94) | 204 (10–7778) | 217 (6–7000) | 163 (32–3346) | 2.9 (0.2–56.7) |
Group I | 48 (0.08–94) | 195 (10–7778) | 236 (7–6247) | 163 (32–3346) | 2.4 (0.2–49.4) |
HEV IgG− HEV IgM− (n = 456) | |||||
Group II | 50 (0.08–93) | 185 (14–7000) | 167 (6–7000) | 170 (41–1422) | 4.3 (0.2–56.7) |
HEV IgG+ HEV IgM− (n = 233) | |||||
Group III | 48.5 (4–59) | 135.5 (30–915) | 330 (19–1974) | 212.5 (173–348) | 1.6 (0.2–9.9) |
HEV IgG− HEV IgM+ (n = 6) | |||||
Group IV | 50 (0.03–91) | 262 (16–3408) | 343 (7–3383) | 163 (51–1348) | 3.9 (0.3–36.7) |
HEV IgG+ HEV IgM+ (n = 101) | |||||
P-value | 0.125 | 0.224 | 0.039* | 0.573 | 0.017* |